Tezosentan

Tezosentan is a vasodilator that is used in the treatment of heart failure. It is a dual endothelin receptor antagonist (ERA) that blocks both ETA and ETB receptors. Tezosentan was developed by Actelion, a Swiss pharmaceutical company.

Mechanism of Action[edit | edit source]

Tezosentan works by blocking the endothelin receptors, ETA and ETB. Endothelin is a potent vasoconstrictor, and by blocking its receptors, Tezosentan prevents vasoconstriction and promotes vasodilation. This helps to reduce the workload on the heart and improve blood flow.

Clinical Trials[edit | edit source]

Tezosentan has been studied in several clinical trials for its efficacy in treating heart failure. The VERITAS trial, for example, evaluated the use of Tezosentan in patients with acute heart failure. However, the results of these trials have been mixed, and Tezosentan is not currently approved for use in the United States.

Side Effects[edit | edit source]

Like all medications, Tezosentan can cause side effects. These may include headache, dizziness, and low blood pressure. In some cases, Tezosentan may also cause fluid retention, which can exacerbate heart failure.

References[edit | edit source]

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

‎

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.